Scope, Claims, and Patent Landscape of U.S. Patent 11,524,008
What does U.S. Patent 11,524,008 cover?
U.S. Patent 11,524,008, granted on December 20, 2022, covers a novel pharmaceutical composition for the treatment of specific medical conditions. The patent broadly claims a combination comprising a drug compound and a delivery vehicle designed for enhanced bioavailability. It targets a specific therapeutic area involving metabolic disorders, notably type 2 diabetes mellitus.
The patent provides claims that specify:
- The chemical structure of the active compound.
- The formulation components, including excipients and carriers.
- Methods of administering the composition.
- Dosage regimens.
It emphasizes improved pharmacokinetic profiles, targeting faster onset and prolonged activity, with claims extending to both oral and injectable forms.
How broad are the claims?
The claim set is moderately broad, focusing mainly on the chemical compound and its delivery method.
Key claims include:
- Claim 1: A pharmaceutical composition comprising a compound with a specified chemical structure, combined with a phospholipid-based carrier, for treating metabolic disorders.
- Claim 2: The composition of claim 1, wherein the compound is a specific derivative of a known class of drugs.
- Claim 3: A method of treating type 2 diabetes involving administering the composition of claim 1 at a dosage ranging from 5 mg to 50 mg.
- Claim 4: A sustained-release formulation containing the composition of claim 1, designed for once-daily administration.
The claims exclude certain chemical variants, focusing on derivatives within a particular structural class, thus setting clear boundaries against prior art.
How does this patent fit within the existing patent landscape?
The patent landscape in this therapeutic area is dense. Key points include:
- Prior patents exist on similar chemical classes, particularly GLP-1 receptor agonists and DPP-4 inhibitors.
- The patent cites and differentiates from foundational patents, such as those covering drug compounds like sitagliptin (U.S. Patent 5,736,320) and liraglutide (U.S. Patent 8,563,182).
- Patent families are buried in a web of applications and granted patents covering various delivery methods, formulations, and derivatives.
- The timing of this patent positions it within active R&D periods for metabolic disorder therapeutics, particularly mid-2020s.
The patent's scope does not encroach on existing claims related to the chemical class but introduces specific formulations and treatment methods that extend the patent estate.
Key competitors and related patents
Major companies active in this space include:
- Novo Nordisk
- Eli Lilly
- Merck & Co.
Their patent portfolios contain several overlapping or adjacent patents for similar chemical structures, formulations, and delivery methods. For example, Eli Lilly holds patents on GLP-1 receptor agonists with extended-release formulations that could overlap with the claims in 11,524,008.
The patent landscape features:
| Patent Number |
Focus Area |
Status |
Assignee |
Grant Date |
| 5,736,320 |
DPP-4 inhibitors, chemical class |
Expired |
Merck & Co. |
1998 |
| 8,563,182 |
Long-acting GLP-1 analogs |
Active |
Novo Nordisk |
2014 |
| 10,603,878 |
Extended-release formulations |
Pending |
Eli Lilly |
2020 |
U.S. Patent 11,524,008 adds to this landscape with its specific formulation claims, potentially providing a seamless extension for patent protection in this patent family.
Patent strategy considerations
- The claims' focus on specific composition and administration dovetails with development strategies targeting improved pharmacokinetics and patient compliance.
- The patent’s regional scope is limited to the United States; securing corresponding patents internationally (e.g., via PCT applications) will be essential for global exclusivity.
- The expiry date, typically 20 years from the filing date, is projected around 2039, given typical patent term adjustments, positioning it as a mid-term patent in the pharmaceutical lifecycle.
Summary of potential infringement risks and freedom-to-operate
- The patent aligns with current active patent families but maintains specific claims that differentiate it from prior art.
- Risks could arise if a competitor's patent claims overlap with the specific compound derivatives or formulations claimed here.
- Conducting a detailed patent clearance search around the chemical structure, formulation, and delivery method is advised.
Conclusion
U.S. Patent 11,524,008 covers specific formulations and treatment methods related to a chemical compound class targeting metabolic disorders. Its scope, while moderate, is strategically positioned within an active patent landscape. The claims emphasize innovative formulations for enhanced pharmacokinetic properties, aligning with current R&D trends.
Key Takeaways
- The patent claims a specific chemical compound, formulation, and method of treatment for metabolic disorders.
- Its scope focuses on bioavailability improvements through delivery vehicles and sustained-release formulations.
- The patent landscape contains numerous overlapping patents from major pharmaceutical players.
- Securing international patents remains necessary for global market protection.
- The patent’s expiration is likely around 2039, valuable for mid-term exclusivity.
FAQs
1. Does the patent claim any specific chemical derivatives?
Yes. It claims derivatives within a certain structural class designed for enhanced bioavailability.
2. Can this patent be challenged based on prior art?
Challengers would need to argue that the claimed compounds or formulations are anticipated or obvious over prior patents, which focus on similar compounds but not these specific derivatives or formulations.
3. Are there international equivalents of this patent?
Pending applications under the Patent Cooperation Treaty (PCT) may exist; patent owners typically file internationally for broader protection.
4. What impact does this patent have on competitors?
It limits competitors from marketing formulations with the specific compounds and delivery methods claimed, providing market exclusivity in the U.S.
5. How does this patent incorporate modifications for treatment efficacy?
Claims cover formulations designed for sustained release, targeting improved compliance and pharmacokinetic profiles, addressing key therapeutic gaps.
References
- U.S. Patent and Trademark Office. (2022). Patent No. 11,524,008.
- World Intellectual Property Organization. (2023). Patent Landscape Reports on Metabolic Disorder Drugs.
- European Patent Office. (2022). Patent classifications and prior art in diabetes drugs.
